Original Research
Monday, November 13, 2023
01:00 PM–02:30 PM
Abstract
Introduction: Continuous glucose monitoring (CGM) devices are alternatives to traditional glucose monitoring, and several devices are currently available on the market. Certain drugs affect CGM blood glucose readings. The availability of these drug-device interactions in tertiary drug information resources is unknown.
Research Question or Hypothesis: How frequently are drug-device interactions with continuous glucose monitors documented in tertiary drug information resources?
Study Design: A descriptive, cross-sectional study analyzing CGM drug-device interactions in tertiary drug information resources.
Methods: CGM devices currently on the market were determined, and their user guides were examined for any information on drug-device interactions. Primary literature on drug-device interactions was assessed to uncover additional interacting drugs. After compiling a list of interacting drugs, available tertiary drug information resources were explored to see if they contained documentation for the drug-device interactions with CGM devices. The tertiary databases explored included: Lexicomp, Clinical Pharmacology, Daily Med, Drugs.com, Micromedex, Epocrates, Clin-Alert and FDA MedWatch. These databases were chosen based upon the Drug Information Handbook list of tertiary resources.
Results: Eight medications were identified to interact with CGM devices: acetaminophen, aspirin, ascorbic acid, hydroxyurea, mannitol, sorbitol, tetracyclines, and dexamethasone. Of the eight databases explored, only Micromedex and Clin-Alert listed drug-device interactions. Micromedex only listed interactions for two of the eight (25%) interacting medications: aspirin and ascorbic acid. Clin-Alert listed interactions for one medication (12.5%), acetaminophen. The tertiary drug information resources did not specify which CGM devices were affected by the drug-device interaction.
Conclusion: Despite these interactions between common medications and CGM devices being listed on the manufacturer sites or in the user guides for the CGM devices, these interactions are not sufficiently reported in tertiary drug information resources. Drug-device interactions should be added to drug monographs in tertiary drug information resources.
Presenting Author
Nicole Campbell PharmDAuthors
Julie Kalabalik PharmD
Fairleigh Dickinson University
Jolie Schojbert PharmD Candidate